Acceleron Pharma (XLRN) Stock Analysis

What Acceleron Pharma does

Acceleron Pharma Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market treatments for severe and uncommon illnesses. Its flagship product, REBLOZYL (luspatercept-aamt), addresses anemia in adult patients afflicted with beta-thalassemia. The company's pipeline includes additional applications for luspatercept-aamt targeting myelodysplastic syndromes and myelofibrosis. Furthermore, it is developing Sotatercept for patients suffering from pulmonary arterial hypertension. A neuromuscular therapeutic candidate, ACE-083, is currently undergoing Phase II clinical trials to treat Charcot-Marie-Tooth disease. Acceleron has also forged strategic alliances, including a collaboration, license, and option pact with Celgene Corporation. Another partnership with Fulcrum Therapeutics, Inc. focuses on a collaboration and license agreement to pinpoint small molecules capable of modulating particular pathways relevant to specific pulmonary conditions. Initially established in 2003 as Phoenix Pharma, Inc., the company, now known as Acceleron Pharma Inc., maintains its headquarters in Cambridge, Massachusetts.

Key metrics

ETFs linked to XLRN

Broad-market and Healthcare sector ETFs an investor holding Acceleron Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how XLRN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Acceleron Pharma?

Acceleron Pharma trades under the ticker XLRN on NASDAQ.

Which exchange is XLRN listed on?

XLRN is listed on NASDAQ.

What sector does Acceleron Pharma operate in?

Acceleron Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze XLRN in a portfolio?

PortView shows XLRN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.